The DOI matches its Crossref record; 99 of the 102 references it cites were found in a registry or an index.
Antipsychotic medications for cocaine dependence
Open accessAbstract
BACKGROUND: Cocaine dependence is a public health problem characterised by recidivism and a host of medical and psychosocial complications. Cocaine dependence remains a disorder for which no pharmacological treatment of proven efficacy exists. OBJECTIVES: To evaluate the efficacy and the acceptability of antipsychotic medications for cocaine dependence. SEARCH METHODS: This review is an update of a previous Cochrane review published in 2007. We searched up to 15 July 2015 in Cochrane Drugs and Alcohol Group Specialised Register (searched in CRSLive); the Cochrane Library (including the Cochrane Central Register of Controlled Trials (CENTRAL); the Database of Abstracts of Reviews of Effects (DARE)); PubMed; EMBASE; CINAHL and Web of Science. All searches included non-English language literature. SELECTION CRITERIA: All randomised controlled trials and controlled clinical trials with focus on the use of any antipsychotic medication for the treatment of cocaine dependence. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 14 studies (719 participants). The antipsychotic drugs studied were risperidone, olanzapine, quetiapine, lamotrigine, aripiprazol, haloperidol and reserpine. Comparing any antipsychotic drugs versus placebo, we found that antipsychotics reduced dropout: eight studies, 397 participants, risk ratio (RR) 0.75 (95% confidence interval (CI) 0.57 to 0.97), moderate quality of evidence. We found no significant differences for any of the other primary outcomes considered: number of participants using cocaine during the treatment, two studies, 91 participants: RR 1.02 (95% CI 0.65 to 1.62); continuous abstinence, three studies, 139 participants: RR 1.30 (95% CI 0.73 to 2.32); side effects, six studies, 291 participants: RR 1.01 (95% CI 0.93 to 1.10); and craving, four studies, 240 participants: RR 0.13 (-1.08 to 1.35). For all of these comparisons we rated the quality of evidence as low.Comparisons of single drug versus placebo or versus another drug are conducted in few trials with small sample sizes, limiting the reliability of the results. Among these comparisons, only quetiapine seemed to outperform placebo in reducing cocaine use, measured by grams per week: mean difference (MD) -0.54 (95% CI -0.92 to -0.16), by US dollars spent per week: MD -53.80 (95% CI -97.85 to -9.75), and by craving: MD -1.23 (95% CI -2.19 to -0.27), but results came from one study with 60 participants.The major limitations of the studies were the high risk of attrition bias (40% of the included studies) and low quality of reporting, mainly for the risk of selection bias, performance and detection bias, that we rated as being at unclear risk for 75% to 80% of the studies. Furthermore, most of the included studies did not report results on important outcomes such as side effects, or use of cocaine during treatment and craving, which prevented the possibility of including them in statistical synthesis. AUTHORS' CONCLUSIONS: At present, there is no evidence supporting the clinical use of antipsychotic medications in the treatment of cocaine dependence, although results come from only 14 trials, with small sample sizes and moderate to low quality of evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is FDA-approved to treat depression, may also help treat anxiety and improve sleep quality, and has no known potential for misuse.128”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [128]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is FDA-approved to treat depression, may also help treat anxiety and improve sleep quality, and has no known potential for misuse.128”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [128]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is FDA-approved to treat depression, may also help treat anxiety and improve sleep quality, and has no known potential for misuse.128”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [128]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is FDA-approved to treat depression, may also help treat anxiety and improve sleep quality, and has no known potential for misuse.128”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [128]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dopamine agonists for cocaine dependence
Soares, B. G., Reisser, A. A. L., Farrell, M., & de Lima, M. S. (2003) · doi:10.1002/14651858.cd003352 · Cited by 83
RetractedAntidepressants for cocaine dependence
de Lima, M. S., Farrell, M., Reisser, A. A. L., & Soares, B. G. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002950 · Cited by 80
RetractedCarbamazepine for cocaine dependence
Reisser, A. A. L., Lima, M., Soares, B., & Farrell, M. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002023 · Cited by 45
RetractedPsychosocial treatments for psychostimulants dependence
Soares, B., Lima, M., & Farrell, M. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003023 · Cited by 14
RetractedDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Flagged first, then by citations
3 of the 102 references couldn’t be matched to a known paper.
Research works printed but not linked: 10
- Brown, 2009, A randomized, double-blind, placebo-controlled pilot study of quetiapine in outpatients with bipolar disorder and cocaine dependence, Bipolar Disorders, 11, 25
- Landabaso, 2003, Olanzapina and cocaine consumption in methadone maintenance programs: new results, Psiquiatría Biológica, 10, 160
- Vazquez, 2009, Clinical trial on the use of olanzapine in reducing the consumption of cocaine in methadone maintenance programmes, Heroin Addiction and Related Clinical Problems, 11, 21
- Middleton L Lofwall M Nuzzo PA Walsh SL Safety of oral aripiprazole alone and in combination with intravenous cocaine in humans Proceedings of the 71st Annual Scientific Meeting of the College on Problems of Drug Dependence; Reno/Sparks, Nevada, USA 2009 102
- Nuzzo PA Lofwall MR Walsh SL Aripiprazole effects on cigarette smoking among cocaine users Proceedings of the 74th Annual Scientific Meeting of the College on Problems of Drug Dependence, Palm Springs, CA , Abstract 2012
- Rush, 2009, Aripiprazole as a pharmacotherapy for cocaine dependence, The American Journal on Addiction, 18, 326
- Beck, 1996, Beck Depression Inventory, 2nd edn
- Guy, 1976, Assessment Manual for Psychopharmacology
- Karch, 1992, A Brief History of Cocaine, 2nd edition
- Sorensen, 1991, Preventing AIDS in Drug Abusers and their Sexual Partners
Cited by
Sorted by citations
Leeman, R. F., & Potenza, M. N. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2550-7 · Cited by 448
Ashok, A. H., Mizuno, Y., Volkow, N. D., & Howes, O. D. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0135 · Cited by 330
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Responding to global stimulant use: challenges and opportunities
Farrell, M., Martin, N. K., Stockings, E., Bórquez, A., Cepeda, J. A., Degenhardt, L., Ali, R., Tran, L. T., Rehm, J., Torrens, M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32230-5 · Cited by 310
Disulfiram for the treatment of cocaine dependence
Pani, P. P., Trogu, E., Vacca, R., Amato, L., Vecchi, S., & Davoli, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007024.pub2 · Cited by 260
Self-citationTreatment of stimulant use disorder: A systematic review of reviews
Ronsley, C., Nolan, S., Knight, R., Hayashi, K., Klimas, J., Walley, A., Wood, E., & Fairbairn, N. (2020) · PLOS ONE · doi:10.1371/journal.pone.0234809 · Cited by 222
Leeman, R. F., & Potenza, M. N. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/070674371305800503 · Cited by 250
Su, F., Zhang, S., Ji, H., Zhao, H., Tian, J., Liu, C., Zhang, Z., Fang, S., Zhu, X., & Du, M. (2017) · ACS Sensors · doi:10.1021/acssensors.7b00268 · Cited by 182
Hurd, Y. L., Yoon, M. J., Manini, A. F., Hernandez, S. H., Olmedo, R., Östman, M., & Jutras‐Aswad, D. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0373-7 · Cited by 171
Bentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M., & Halpern, C. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8049 · Cited by 161
Tardelli, V. S., Bisaga, A., Arcadepani, F. B., Gerra, G., Levin, F. R., & Fidalgo, T. M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05563-3 · Cited by 151
Pharmacotherapy for Cocaine Use Disorder—a Systematic Review and Meta-analysis
Chan, B., Kondo, K., Freeman, M., Ayers, C., Montgomery, J., & Kansagara, D. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05074-8 · Cited by 150
Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment
Brierley, D. I., & Davidson, C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.001 · Cited by 138
Anticonvulsants for cocaine dependence
Minozzi, S., Cinquini, M., Amato, L., Davoli, M., Farrell, M., Pani, P. P., & Vecchi, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006754.pub4 · Cited by 131
Self-citationEvidence-Based Pharmacological Treatment of Substance Use Disorders and Pathological Gambling
van den Brink, W. (2012) · Current Drug Abuse Reviews · doi:10.2174/1874473711205010003 · Cited by 117
Ersche, K. D., Bullmore, E. T., Craig, K. J., Shabbir, S. S., Abbott, S., Müller, U., Ooi, C., Suckling, J., Barnes, A., Sahakian, B. J., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.60 · Cited by 108
Dopamine agonists for the treatment of cocaine dependence
Minozzi, S., Amato, L., Pani, P. P., Solimini, R., Vecchi, S., Crescenzo, F. D., Zuccaro, P., & Davoli, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003352.pub4 · Cited by 108
Self-citationHerin, D. V., Rush, C. R., & Grabowski, J. G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05145.x · Cited by 101
Pharmacotherapeutic strategies for treating cocaine use disorder—what do we have to offer?
Brandt, L., Chao, T., Comer, S., & Levin, F. (2020) · Addiction · doi:10.1111/add.15242 · Cited by 80
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Fischer, B., Blanken, P., da Silveira, D. X., Gallassi, A. D., Goldner, E. M., Rehm, J. T., TYNDALL, M. W., & Wood, E. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.01.002 · Cited by 76
Cocaine Use Disorder (CUD): Current Clinical Perspectives
Schwartz, E. K. C., Wolkowicz, N. R., Aquino, J. P. D., MacLean, R. R., & Sofuoglu, M. (2022) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s337338 · Cited by 92
Agonist Medications for the Treatment of Cocaine Use Disorder
Negus, S. S., & Henningfield, J. E. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.322 · Cited by 72
Drug screening in Drosophila; why, when, and when not?
Su, T. T. (2019) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.346 · Cited by 69
Mongeau‐Pérusse, V., Brissette, S., Bruneau, J., Conrod, P., Dubreucq, S., Gazil, G., Stip, É., & Jutras‐Aswad, D. (2021) · Addiction · doi:10.1111/add.15417 · Cited by 64
Aripiprazole maintenance increases smoked cocaine self-administration in humans
Haney, M., Rubin, E., & Foltin, R. W. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2231-6 · Cited by 62
The role of dopamine in inhibitory control in smokers and non-smokers: A pharmacological fMRI study
Luijten, M., Veltman, D. J., Hester, R., Smits, M., Nijs, I. M. T., Pepplinkhuizen, L., & Franken, I. H. A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.10.017 · Cited by 62
Chan, B., Freeman, M., Ayers, C., Korthuis, P. T., Paynter, R., Kondo, K., & Kansagara, D. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108193 · Cited by 56
Cuomo, I., Kotzalidis, G. D., Persis, S. D., Piacentino, D., Perrini, F., Amici, E., & Filippis, S. D. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s171002 · Cited by 58
The Benefits of Olanzapine in Palliating Symptoms
Davis, M. P., & Sanger, G. J. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00804-1 · Cited by 54
Pharmacological treatments for cocaine dependence: is there something new?
Karila, L., Reynaud, M., Aubin, H., Rolland, B., Guardia, D., Cottencin, O., & Benyamina, A. (2011) · Current pharmaceutical design · doi:10.2174/138161211796150873 · Cited by 52
Substance use in older HIV-infected patients
Edelman, E. J., Tetrault, J. M., & Fiellin, D. A. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000069 · Cited by 49
Abdulrahim, D., & Bowden‐Jones, O. (2015) · Cited by 46
Peacock, A., Tran, L., Larney, S., Stockings, E., Santo, T., Jones, H., Santomauro, D., & Degenhardt, L. (2020) · Addiction · doi:10.1111/add.15239 · Cited by 31
Mooney, M. E., Herin, D. V., Specker, S. M., Babb, D. A., LEVIN, F. R., & Grabowski, J. G. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.05.042 · Cited by 44
Olière, S., Joliette-Riopel, A., Potvin, S., & Jutras‐Aswad, D. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00109 · Cited by 41
Nuijten, M., Blanken, P., van den Brink, W., & Hendriks, V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.02.024 · Cited by 38
Stoops, W. W., & Rush, C. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.909283 · Cited by 39
Antipsychotic drugs in cocaine dependence: a systematic review and meta-analysis.
Alvarez, Y., Pérez-Mañá, C., Torrens, M., & Farré, M. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2012.12.013 · Cited by 32
Pérez-Mañá, C., Castells, X., Vidal, X., Casas, M., & Capellà, D. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.08.012 · Cited by 33
Medications to treat cocaine use disorders: current options.
Buchholz, J., & Saxon, A. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000518 · Cited by 27
Quetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review
Vento, A. E., Kotzalidis, G. D., Cacciotti, M., Papanti, G. D., Orsolini, L., Rapinesi, C., Savoja, V., Calabrò, G., CASALE, A. D., Piacentino, D., et al. (2019) · Substance Use & Misuse · doi:10.1080/10826084.2019.1668013 · Cited by 33
Psychopharmacological Treatment in Pathological Gambling: A Critical Review
Achab, S., & Khazaal, Y. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796150774 · Cited by 32
Szerman, N., Basurte-Villamor, I., Vega, P., Martı́nez-Raga, J., Parro-Torres, C., Almerge, J. C., Grau‐López, L., Matteis, M. D., & Árias, F. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-020-00178-8 · Cited by 32
Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review
Lassi, D., Malbergier, A., Negrão, A., Florio, L., de Aquino, J. D., & Castaldelli-Maia, J. (2022) · Brain Science · doi:10.3390/brainsci12111546 · Cited by 25
Anticonvulsant drugs in cocaine dependence: A systematic review and meta-analysis
Alvarez, Y., Farré, M., Fonseca, F., & Torrens, M. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.07.001 · Cited by 36
Beresford, T. P., Buchanan, J., Thumm, E. B., Emrick, C. D., Weitzenkamp, D. A., & Ronan, P. J. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000789 · Cited by 30
Contingency Management with pharmacologic treatment for Stimulant Use Disorders: A review
Tardelli, V. S., do Lago, M. P. P., Mendez, M., Bisaga, A. M., & Fidalgo, T. M. (2018) · Behaviour Research and Therapy · doi:10.1016/j.brat.2018.10.002 · Cited by 30
Fortier, E., Sylvestre, M., Artenie, A. A., Minoyan, N., Jutras‐Aswad, D., Roy, É., Grebely, J., & Bruneau, J. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107744 · Cited by 29
Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration
Anastasio, N. C., Sholler, D. J., Fox, R. G., Stutz, S. J., Merritt, C. R., Bjork, J. M., Moeller, F. G., & Cunningham, K. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108009 · Cited by 26
Human pharmacology for addiction medicine
Quednow, B. B., & Herdener, M. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.017 · Cited by 27
Do Placebo Response Rates from Cessation Trials Inform on Strength of Addictions?
Moore, R. A., & Aubin, H. (2012) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph9010192 · Cited by 24
Mechanistic insights into the efficacy of memantine in treating certain drug addictions
Montemitro, C., Angebrandt, A., Wang, T., Pettorruso, M., & Abulseoud, O. A. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110409 · Cited by 24
Nuijten, M., Blanken, P., van den Brink, W., & Hendriks, V. M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115582151 · Cited by 23
Pharmacological interventions to modulate attentional bias in addiction
Luijten, M., Field, M., & Franken, I. H. A. (2013) · CNS Spectrums · doi:10.1017/s1092852913000485 · Cited by 23
Nuijten, M., Blanken, P., van den Brink, W., & Hendriks, V. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-135 · Cited by 24
Office-Based Addiction Treatment in Primary Care
Edelman, E. J., Oldfield, B. J., & Tetrault, J. M. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.007 · Cited by 21
Leung, J. C. N., Ng, D. W. Y., Chu, R. Y. K., Chan, E. W. W., Huang, L., Lum, D. H., Chan, E. W., Smıth, D. J., Wong, I. C. K., & Lai, F. T. T. (2022) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796022000476 · Cited by 18
Hutsell, B. A., Negus, S., & Banks, M. L. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.08.637 · Cited by 18
Li, C., McCloskey, N. S., Phillips, J., Simmons, S. J., & Kirby, L. G. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05652-3 · Cited by 18
New medications for the treatment of cocaine dependence.
Kampman, K. M. (2009) · PubMed · Cited by 16
Blanken, P., Nuijten, M., van den Brink, W. J., & Hendriks, V. (2019) · Addiction · doi:10.1111/add.14874 · Cited by 15
Lynch, W. J., Bakhti‐Suroosh, A., Abel, J. M., & Davis, C. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05732-4 · Cited by 13
Cénat, J. M., Kogan, C. S., Kebedom, P., Ukwu, G., Farahi, S. M. M. M., Darius, W. P., Bakombo, S. M., Dalexis, R. D., Ndengeyingoma, A., Noorishad, P., et al. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107567 · Cited by 12
Schaub, M. P., Castro, R. P., Wenger, A., Baumgartner, C., Stark, L., Ebert, D. D., Quednow, B. B., & Haug, S. (2019) · Internet Interventions · doi:10.1016/j.invent.2019.100251 · Cited by 16
Disulfiram for the treatment of cocaine dependence
Traccis, F., Minozzi, S., Trogu, E., Vacca, R., Vecchi, S., Pani, P. P., & Agabio, R. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007024.pub3 · Cited by 14
Self-citationTardelli, V., Berro, L. F., Gerra, G., Tadonio, L., Bisaga, A., & Fidalgo, T. (2023) · Addiction Biology · doi:10.1111/adb.13271 · Cited by 11
Double-blind evaluation of homeopathy on cocaine craving: a randomized controlled pilot study
Adler, U. C., Acorinte, A. C., Calzavara, F. O., da Silva, A. A., César, A. D. T., Adler, M. S., Martínez, E. Z., & Galduróz, J. C. F. (2018) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2018.03.004 · Cited by 11
Blevins, D., Seneviratne, C., Wang, X.-Q., Johnson, B. A., & Ait‐Daoud, N. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109074 · Cited by 11
Roger-Sánchez, C., Rodríguez‐Arias, M., Miñarro, J., & Aguilar, M. A. (2013) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.07.009 · Cited by 10
Addictions à l'héroïne et à la cocaïne
Dervaux, A., & Laqueille, X. (2009) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(09)48129-x · Cited by 10
Management of withdrawal from alcohol and other drugs
Lintzeris, N., Sunjic, S., Demirkol, A., Branezac, M., Ezard, N., Siefried, K. J., Acheson, L. S., Bascombe, F., Tremonti, C., & Haber, P. (2019) · doi:10.57022/mjjp9930 · Cited by 9
Mann, K. F., Berner, M. M., & Günthner, A. (2012) · Elsevier eBooks · doi:10.1016/b978-3-437-22483-6.10009-9 · Cited by 8
Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia
Wehring, H. J., Heishman, S. J., McMahon, R. P., Liu, F., Feldman, S. M., Raley, H., Weiner, E., & Kelly, D. L. (2017) · Journal of Dual Diagnosis · doi:10.1080/15504263.2017.1288946 · Cited by 8
Verbič, M. D., Grabnar, I., Eyer, F., & Brvar, M. (2024) · Journal of Xenobiotics · doi:10.3390/jox14040085 · Cited by 7
Ferri, M., Bò, A., Amato, L., Guedes, I. C., Esteves, C. S., Wiessing, L. G., Oliver, S. R., Hickman, M., & Davoli, M. (2014) · Drugs Education Prevention and Policy · doi:10.3109/09687637.2014.954988 · Cited by 7
Self-citationPharmacology of Geriatric Substance Use Disorders: Considerations and Future Directions
Hassell, C., Wilkins, K. M., & Trevisan, L. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0107-z · Cited by 6
Similarities and Differences in Neurobiology
Manli, C., Sun, Y., Lu, L. N., & Shi, J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-5562-1_3 · Cited by 6
Lack of dopamine D4 receptor participation in mouse hyperdopaminergic locomotor response
Liao, I.-M., & Chen, J. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112925 · Cited by 6
Addiction à la cocaïne et au « crack » : un problème de santé publique qui s’aggrave
Haas, C. D., Karila, L., & Lowenstein, W. (2009) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32535-x · Cited by 6
Grasing, K. W., Burnell, K., & De, A. (2022) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000672 · Cited by 4
Batra, A., Mann, K. F., Berner, M. M., & Günthner, A. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-22485-0.00009-9 · Cited by 4
Dopaminergic antagonists for alcohol dependence
de Lima, F. B. V., Andriolo, R. B., & da Silveira, D. X. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008460 · Cited by 4
RetractedUsing Behavioral Incentives to Promote Exercise Compliance in Women with Cocaine Dependence
Islam, L. Z. (2013) · PubMed · doi:10.25772/4v0f-7e81 · Cited by 3
Novel Pharmacological Agents for the Treatment of Cocaine Use Disorder
Hadizadeh, H., Flores, J. M., Nunes, E. J., Mayerson, T. F., Potenza, M. N., & Angarita, G. A. (2022) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-022-00246-z · Cited by 3
Lack of effect of the combination of metyrapone and oxazepam on brain dopamine
Keller, C. M., & Goeders, N. E. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146435 · Cited by 3
Mendelevich, В. D. (2015) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20151154259-63 · Cited by 3
Cocaïne et cocaïnomanie. Enseignements récents et stratégies actuelles
Lacoste, J., Michel, G., Rollier, S., & Charles-Nicolas, A. (2018) · Annales Médico-psychologiques, revue psychiatrique · doi:10.1016/j.amp.2018.08.015 · Cited by 1
Cocaine Addiction and Treatment
Gorelick, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-36391-8_13
Non-invasive brain stimulation in craving disorders: evidence-based umbrella review
Sá, K. N., Goulardins, J. B., Sá, M. N., Baptista, R. F., Tanaka, C., Shirahige, L., Monte-Silva, K. K., & Baptista, A. F. (2023) · Brain Imaging and Stimulation · doi:10.17267/2965-3738bis.2023.e5296 · Cited by 2
Clergue‐Duval, V., Lyonnet, A., Azuar, J., Icick, R., Poireau, M., Rollet, D., Taright, N., Questel, F., Gasquet, I., & Vorspan, F. (2024) · Therapies · doi:10.1016/j.therap.2024.03.001 · Cited by 2
Disorders due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_26 · Cited by 3
Ivanets, N. N., Винникова, М. А., Ежкова, Е. В., Titkov, M. S., & Булатова, Р. А. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201911909152 · Cited by 2
Will hope triumph over experience in pharmacotherapy research on cocaine use disorder?
Humphreys, K. N. (2020) · Addiction · doi:10.1111/add.15266 · Cited by 2
Disul.ram for cocaine dependence
Cubells, J. F. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0012-4 · Cited by 2
Laborde-Rouzaud, C., Rouch, L., Chautant, F., Calvet, P., Sallerin, B. A.-M., Tiravy, J., & Cestac, P. (2014) · Le Pharmacien Hospitalier et Clinicien · doi:10.1016/j.phclin.2013.11.005 · Cited by 2
COCAÍNA História, Acções Neurobiológicas do Vício e Recaída e Perspectivas Terapêuticas
Silva, M. I. G., Citó, M. D. C. D. O., Vasconcelos, P. F. C., Vasconcelos, S. M. M., & de Sousa, F. C. F. (2010) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.20344/amp.609 · Cited by 2
Batra, A., Mann, K. F., Berner, M. M., & Günthner, A. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22484-3.00009-8 · Cited by 2
Consumo de basuco: aspectos relevantes para su tratamiento
Prada, C. R., Peralta, E. R. B., Lugo, G. F. O., & Garzón, R. G. C. (2022) · Universitas Médica · doi:10.11144/javeriana.umed63-1.basu · Cited by 2
Dopamine Receptors: Neurotherapeutic Targets for Substance Use Disorders
Nilson, A. N., Felsing, D. E., & Allen, J. (2022) · Wiley eBooks · doi:10.1002/9781119564782.ch19 · Cited by 2
Metadata
- Authors
- Indave, B. I., Minozzi, S., Pani, P. P., & Amato, L.
- Affiliations
- European Monitoring Centre for Drugs and Drug Addiction (PT)
- Lazio Regional Health Service; Department of Epidemiology; Via Cristoforo Colombo, 112 Rome Italy 00154
- Health District 8 (ASL 8) Cagliari; Social-Health Division; Via Romagna 17 Cagliari Sardinia Italy 09128
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-03-19
- Volume
- 2016
- Issue
- 6
- Pages
- CD006306-CD006306
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC8750745
- OpenAlex
- W1507790507
- Cited by
- 122
- References
- 102
- Citations by year
- 2024: 9 · 2023: 4 · 2022: 9 · 2021: 4 · 2020: 14 · 2019: 13 · 2018: 5 · 2017: 9 · 2016: 2
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- cocaine dependence, antipsychotic drugs, pharmacotherapy, risperidone, olanzapine, quetiapine, lamotrigine, aripiprazole, haloperidol, reserpine, cocaine abstinence, treatment discontinuation, craving, adverse effects, treatment acceptability, relapse, substance use disorders, placebo comparison, drug comparison, quality of evidence
- MeSH terms
- Aripiprazole, Quetiapine Fumarate, Olanzapine, Lamotrigine, Benzodiazepines, Haloperidol, Humans, Patient Dropouts, Reserpine, Antipsychotic Agents, Triazines, Randomized Controlled Trials as Topic, Risperidone, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review